Stay updated on Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial

Sign up to get notified when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:18:33.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety evaluation of deucravacitinib versus placebo for the treatment of participants with active Psoriatic Arthritis.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:05.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals diagnosed with psoriatic arthritis (PsA) for at least 3 months and meeting the CASPAR criteria. Previously, this section had no information provided.
    Difference
    9%
    Check dated 2024-05-22T20:56:29.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:35:41.000Z thumbnail image

Stay in the know with updates to Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.